BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $104
Benzinga Newsdesk 1 year ago
NewsPrice TargetSmall CapAnalyst Ratings
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $87 to $104.
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ: MNPR) with a Buy and raises the price target from $87 to $104.